Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution

Table 1 Demographic and clinical characteristics

Characteristic	DPYD testing, n = 149	No DPYD testing, n = 151	Total, n = 300
Median age	66 (84-33)	65 (85-34)	65 (85-33)
ECOG PS
0	133 (89)	143 (95)	276 (92)
1	16 (11)	8 (5)	24 (8)
Sex
Male	79 (53)	86 (57)	165 (55)
Female	70 (47)	65 (43)	135 (45)
Type of cancer
Colon	80 (54)	87 (58)	167 (55.7)
Rectal	32 (21)	46 (30)	78 (26)
Gastric	29 (19)	16 (11)	45 (15)
Esophageal	1 (1)	0 (0)	1 (0.3)
Anal	7 (5)	1 (1)	8 (2.7)
Appendiceal	0 (0)	1 (1)	1 (0.3)
Stage of disease
Localized	104 (70)	95 (63)	199 (66.3)
Metastatic	45 (30)	56 (37)	101 (33.7)
Type of treatment
Monotherapy	23 (15)	20 (13)	43 (14)
Monotherapy + RT	20 (13)	34 (23)	54 (18)
Doublet	97 (65)	88 (58)	185 (61.7)
Triplet	9 (6)	9 (6)	18 (6)

Data are n (%). ECOG: Eastern cooperative oncology group; PS: Performance Status; RT: Radiotherapy.